Globenewswire: KemPharm Inc., a specialty pharmaceutical company in Coralville, reported a loss of $13.4 million, or 92 cents a share, in its third quarter, compared with a loss of $9.7 million, or 68 cents a share, in the quarter a year ago. The company said the loss was driven primarily by $3 million in severance expenses related to the deferral of commercial operations and realignment of financial resources and operational priorities. It is focusing on two products as its priorities for regulatory approval — one for treatment of attention deficit hyperactivity disorder and one for treatment of acute pain.